Authors: Feng Y, Zhu S, Skiadaresi E, McAlinden C, Tu R, Gao R, et al.
Geographical coverage: Saudi Arabia, Spain, Japan, Iran and China
Sector: Biomedical
Sub-sector: Treatment
Equity focus: Not reported
Study population: Patients with diabetic macular edema
Review type: Effectiveness review
Quantitative synthesis method: Meta-analysis
Qualitative synthesis method: Not applicable
Background: Cataract surgery increases the risk of diabetic retinopathy (DR) and diabetic macular edema (DME). These risks are lowered by using intravitreal anti-vascular endothelial growth factor (VEGF) therapy with cataract surgery. Although several comparative studies assessed efficacy of intravitreal bevacizumab (IVB) with cataract surgery to lower the risk of DR progression, the results were not consistent.
Objectives: To evaluate the clinical effectiveness of intravitreal bevacizumab (IVB) injection combined with cataract surgery in the treatment of patients with cataract and coexisting diabetic retinopathy (DR).
Main findings: A total of 55 articles were identified from the electronic database and manual reference searches, of which six were included in this review. Five of the six included studies were randomised control trials (RCTs) and one was a cohort study. Two of the six studies were conducted in Iran, and one each in Saudi Arabia, Spain, Japan and China. The findings of meta-analysis showed that at one and three months after cataract surgery, corrected distance vision acuity (CDVA) was significantly better in the IVB groups than in control groups (p<0.00001 and p = 0.01); however, CDVA did not differ significantly between the two groups (p = 0.24) at six months post-surgery. Similarly, at one, three and six months after cataract surgery, the central macular thickness (CMT) was significantly thinner in IVB groups than in control groups (p = 0.01, p = 0.0004, and p = 0.01). Sensitivity analyses conducted for CDVA and CMT did not alter the results. The progression of postoperative DR (p = 0.0001) and maculopathy (p<0.0001) occurred more frequently in the control group than in the IVB group.
The authors concluded that IVB injections combined with cataract surgery was safe and effective for patients with coexisting DR for up to six months; and proposed to conduct more randomised, prospective, and large sample-sized studies to assess the long-term effects of intravitreal anti-VEGF therapy at the time of cataract surgery in patients with DR.
Methodology: Searches were conducted in PubMed, EMBASE and Cochrane Controlled Trials Register databases to identify studies comparing cataract surgery with or without IVB therapy in patients with DME. Searches were restricted to articles published in the English language from inception to 1 March 2016. Reference lists of the included studies and relevant review articles were manually reviewed to identify any additional studies.
Randomised controlled and cohort studies conducted on patients aged 18 years and older, with cataract and preexisting DR, who were scheduled for cataract surgery alone (control group) or combined with an IVB injection at the end of surgery (IVB group) were included. In addition, to be included in the study, all patients must have received similar routine medication preoperatively and postoperatively and must not receive further IBV during the minimum three-month follow-up.
The results were synthesised using meta-analysis. Two reviewers conducted screening, data extraction and quality appraisal. The reviewers assessed the risk of bias in the included studies using Cochrane Collaboration’s risk-of-bias tool. Heterogeneity was assessed using Chi2 and I2 statistics. Sensitivity analysis was conducted by excluding non-randomised control trials or studies including patients without DME. Publication bias was assessed using the funnel plot test.
Applicability/external validity: The review did not discuss generalisability of the results.
Geographic focus: Included studies were conducted in Saudi Arabia, Spain, Japan, Iran and China. Authors did not report how findings of this review may be applicable to low and middle income settings.
Summary of quality assessment:
The conclusions of this review are regarded with low confidence due to the identified shortcomings in the review methodology. The literature search was confined to peer-reviewed articles written solely in English. Furthermore, studies with different levels of bias were not individually reported and analysed based on their bias status.
Publication Source:
Feng Y, Zhu S, Skiadaresi E, McAlinden C, Tu R, Gao R, Stephens JW, Wang Q, Huang J. Phacoemulsification cataract surgery with prophylactic intravitreal bevacizumab for patients with coexisting diabetic retinopathy: a meta-analysis. Retina. 2019 Sep;39(9):1720-1731. doi: 10.1097/IAE.0000000000002221. PMID: 29975344.
Downloadable link https://pubmed.ncbi.nlm.nih.gov/29975344/
© 2025 by Sightsavers, Inc., Business Address for all correspondence: One Boston Place, Suite 2600, Boston, MA 02108.
To make sure you have a great experience on our site, we’d like your consent to use cookies. These will collect anonymous statistics to personalise your experience.
You have the option to enable non-essential cookies, which will help us enhance your experience and improve our website.
These enable our site to work correctly, for example by storing page settings. You can disable these by changing your browser settings, but some parts of our website will not work as expected.
To improve our website, we’d like to collect anonymous data about how you use the site, such as which pages you read, the device you’re using, and whether your visit includes a donation. This is completely anonymous, and is never used to profile individual visitors.
To raise awareness about our work, we’d like to show you Sightsavers adverts as you browse the web. By accepting these cookies, our advertising partners may use anonymous information to show you our adverts on other websites you visit. If you do not enable advertising cookies, you will still see adverts on other websites, but they may be less relevant to you. For info, see the Google Ads privacy policy.